

Lifetime Probability of Developing (2017-2019) or Dying (2018-2020) from Cancer

	MALES				FEMALES			
	Developing		Dying		Developing		Dying	
	%	1 in...	%	1 in...	%	1 in...	%	1 in...
All Sites*	41.6	2	19.0	5	39.6	3	17.0	6
Brain & ONS	0.7	145	0.5	192	0.5	186	0.4	243
Breast	0.1	726	<0.1	3,476	13.0	8	2.5	41
Colorectal	4.3	23	1.6	61	3.9	25	1.5	67
Esophagus	0.8	127	0.7	144	0.2	434	0.2	536
Hodgkin lymphoma	0.2	431	<0.1	2,956	0.2	527	<0.1	4,071
Kidney & renal pelvis	2.3	43	0.5	183	1.4	73	0.3	330
Larynx	0.5	197	0.2	594	0.1	844	<0.1	2,416
Leukemia	1.9	53	0.9	115	1.3	75	0.6	159
Liver & intrahepatic bile duct	1.5	65	1.0	100	0.7	143	0.5	182
Lung & bronchus	6.3	16	4.4	23	5.9	17	3.8	26
Melanoma of skin†	3.6	28	0.4	248	2.5	41	0.2	473
Myeloma	1.0	103	0.4	232	0.8	131	0.4	284
Non-Hodgkin lymphoma	2.4	42	0.7	136	1.9	52	0.6	176
Oral cavity & pharynx	1.7	59	0.4	248	0.7	139	0.2	541
Ovary	--	--	--	--	1.1	87	0.8	130
Pancreas	1.7	58	1.4	74	1.7	60	1.3	74
Prostate	12.9	8	2.3	44	--	--	--	--
Stomach	1.0	101	0.4	260	0.6	155	0.3	371
Testis	0.4	244	<0.1	4,889	--	--	--	--
Thyroid	0.7	153	0.1	1,780	1.7	58	0.1	1,467
Urinary bladder‡	3.6	28	0.8	119	1.1	89	0.3	311
Uterine cervix	--	--	--	--	0.7	152	0.2	473
Uterine corpus	--	--	--	--	3.1	32	0.7	153

*All sites excludes basal cell and squamous cell skin cancers and in situ cancers except urinary bladder.

†Statistics are for non-Hispanic Whites.

‡Includes invasive and in situ cancer cases.

Source: Software: DevCan: Probability of Developing or Dying of Cancer Software, Version 6.9.0, National Cancer Institute, 2023.

